Abstract：Objective: To study application of benazepril in maintenance hemodialysis patients and its effects on insulin resistance and lipid metabolism disorder. Methods: 85 patients who underwent maintenance hemodialysis in our hospital from March 2015 to March 2017 were selected for the study, the randomized table was divided into the observation group (n=45) and the control group (n=40). The control group was treated with maintenance hemodialysis, and the observation group was treated with benazepril on the basis of the control group. The changes of fasting insulin (FINS), insulin resistance index (homa-ir), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (ldl-c), high-density lipoprotein cholesterol (hdl-c), connective tissue growth factor (CTGF), endothelin-1 level and adverse reactions were compared between the two groups after treatment. Results: Before treatment, there was no significant difference in the level of FINS and homa-ir between the two groups. After treatment, the levels of females and homa-ir in both groups significantly decreased, and the levels of FINS and homa-ir in the observation group were significantly lower than those in the control group (P < 0.05). Before treatment, there was no significant difference in serum lipid level between the two groups. After treatment, serum lipid levels of both groups increased, and HDL-C decreased. TC, TG and ldl-c levels of the observation group were significantly lower than those of the control group (P < 0.05). There was no statistically significant difference in HDL-C level (P>0.05). Before treatment, there was no significant difference in serum CTGF and et-1 level between the two groups. After treatment, the serum CTGF and et-1 levels of both groups were significantly decreased, and the serum CTGF and et-1 levels of the observation group were significantly lower than those of the control group (P<0.05). The total incidence of dizziness, diarrhea, hypotension and hyperkalemia in the two groups was 8.89% and 22.50%, respectively, without significant difference (P>0.05). Conclusion: Benazepril is effective in the treatment of maintenance hemodialysis patients, which can effectively improve insulin resistance and lipid metabolism disorders, and is worthy of clinical application.
薛辉, 闫晓辉, 梁磊, 王媛. 贝那普利在维持性血液透析患者中的应用及对胰岛素抵抗脂代谢紊乱的影响[J]. 河北医学, 2019, 25(9): 1442-1446.
XUE Hui, YAN Xiaohui, LIANG Lei, et al. Application of Benazepril in Maintenance Hemodialysis Patients and Its Effect on Insulin Resistance and Lipid Metabolism Disorder. HeBei Med, 2019, 25(9): 1442-1446.
[1] 叶白如,谷禾,杨午红,等.老年慢性肾衰竭维持性血液透析患者医院感染相关因素分析[J].中华医院感染学杂志,2015,25(10):2247~2249. [2] Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study[J]. American Journal of Kidney Diseases, 2016, 67(6):912~924. [3] 杜晓娅,吕莉娜,魏磊,等.老年维持性血液透析患者脂联素水平与心脑血管事件及生存率的相关性[J].中华老年心脑血管病杂志,2014,16(9):932~934. [4] Hu F, Zhong Q, Gong J, et al. Serum surfactant protein D is associated with atherosclerosis of the carotid artery in patients on maintenance hemodialysis[J]. Clinical Laboratory, 2016, 62(1-2):97~104. [5] 李文宏,陈浩,翁晓春,等.不同血液净化模式对终末期糖尿病肾病患者胰岛素抵抗及微炎症状态的影响[J].山东医药,2015,55(4):34~36. [6] Beberashvili I, Erlich A, Azar A, et al. Longitudinal study of serum uric acid, nutritional status and mortality in maintenance hemodialysis patients.[J]. Clin Am Soc Nephrol, 2016, 11(6):1015~1023. [7] 赵俊丽,丁发贤,王娟丽.非糖尿病腹膜透析患者胰岛素抵抗与颈动脉粥样硬化的相关性[J].中国动脉硬化杂志,2016,24(4):401~404. [8] 宋小丽,高雪静.贝那普利联合硝苯地平对血液透析患者心脏功能及血清TGF-β、内皮素-1的影响[J].国际检验医学杂志,2017,38(21):3053~3055.
2019, Vol. 25 
冀公网安备13080202000677号